Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Stem cell therapies might help with hair loss, but more research is needed to confirm their safety and effectiveness.

This review highlights advancements in the understanding and treatment of alopecia areata, noting that the approval of oral Janus kinase inhibitors like baricitinib and ritlecitinib marks a significant development in managing severe cases of this autoimmune condition.

This review compiles current insights into alopecia areata's epidemiology, immune mechanisms, diagnosis, treatment options, including novel JAK inhibitors, and its severe psychosocial impact, while also highlighting emerging research areas.

This source reviews alopecia areata, highlighting its epidemiology, immune-related causes, diagnostic methods, and the shift in treatment with JAK inhibitors like baricitinib and ritlecitinib, marking the first disease-modifying options for this hair loss condition.

This review highlights the demonstrated efficacy and growing use of upadacitinib for cutaneous disorders, emphasizing its cost-effectiveness and recent availability in India compared to other biologics and small-molecule therapies, rather than providing new primary data.

This study reports that FDA-approved scalp cooling caps, like DigniCap and Paxman, can help 50-66% of breast cancer patients retain at least 50% of their hair during chemotherapy, with specific recommendations and limitations discussed for different patient groups.

This narrative account, reported by C&EN, describes how Houston's use of a hormone-related hair loss treatment may have triggered unexpected panic attacks, contributing to ongoing mental health challenges, and highlights broader issues with mental health disorders that resist traditional treatments.

This narrative review concludes that long-term randomized controlled trials are needed to establish clear guidelines for testosterone therapy in women, given the lack of FDA-approved formulations and the variable quality of current treatments.

This narrative review found that while exosome-based therapies hold regenerative potential for skin rejuvenation, wound healing, and hair restoration, significant challenges, including variability in manufacturing and lack of regulatory approval, necessitate careful integration into dermatology practice, emphasizing the importance of patient safety and regulatory understanding.

This review discusses the mechanisms, scientific support, and FDA clearance of photobiomodulation mask devices but reports no new research findings.

This article highlights the rising interest in Janus kinase inhibitors for alopecia areata, especially following the FDA approval of baricitinib, underscoring the need for better patient education and physician guidance in selecting appropriate treatments for hair loss.

This abstract does not report specific findings but notes that topical minoxidil, available in 2% and 5% formulations, is widely used and FDA-approved for treating androgenetic alopecia in both men and women, with a strong safety profile.

This study examined the cardiovascular safety of oral minoxidil, used off-label for androgenetic alopecia, particularly as its usage expands in real-world settings, although specific results were not detailed in the abstract.

The researchers reported that oral finasteride 1 mg was associated with more frequent reports of sexual adverse events than dutasteride 0.5 mg, particularly after 2012, which may be influenced by the nocebo effect.

This case study reports a rare instance of both alopecia areata and fixed drug eruption occurring in the same area on a 40-year-old man's beard, triggered by oral paracetamol, highlighting potential shared pathogenic pathways and the isotopic phenomenon.

This review discusses forensic DNA phenotyping and its potential applications, particularly for human identification in Latin American populations, but notes challenges due to genetic diversity and reports no new results.

Low-dose oral minoxidil may be a promising alternative to topical minoxidil for hair loss.

This analytical review of alopecia treatments in the US found that drugs like minoxidil and finasteride are most affordable and effective, while newer JAK inhibitors show significant clinical results but are cost-prohibitive; the study stresses individualizing treatment based on financial capability and alopecia type.

This retrospective pharmacovigilance study identified 34 drugs, including finasteride and dutasteride, that may be associated with sexual dysfunction, with a higher risk observed in males aged 31-45.

Minoxidil can temporarily increase hair shedding, causing anxiety and treatment discontinuation.

Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.

This review reports that while current treatments for non-scarring alopecia, like minoxidil and finasteride, have limited efficacy due to side effects, natural remedies may offer more effective management with potentially fewer side effects, though their varying safety profiles call for further investigation.

This review examines existing studies on male androgenetic alopecia treatments, recommending topical minoxidil and oral finasteride as primary options, without presenting new clinical findings.

This study observed that public interest in JAK-inhibitor treatments for alopecia areata significantly increased around the FDA approval in 2022 and heightened media coverage, suggesting an important role for patient education about these treatments.

This systematic review found that both oral and topical minoxidil have similar efficacy in improving hair density and terminal hair density among patients with androgenetic alopecia, suggesting that oral minoxidil may be a viable second-line or adjunct treatment option.

This study found that reports of suicidal ideations linked to oral finasteride were significantly higher in 2013–2018 and 2019–2023 compared to 2006–2011, potentially due to increased awareness of post-finasteride syndrome from 2012 onward. No such signals were seen with oral dutasteride.

This study analyzed adverse event reports from the FDA Adverse Event Reporting System and identified new side effects of topical minoxidil, such as application site acne and cysts, which are not well-documented on product labels, suggesting a need for updated safety information.

The study by Godfrey et al. highlights a potential link between GLP-1 receptor agonists, specifically semaglutide and tirzepatide, and the risk of alopecia, emphasizing the need for further investigation and patient awareness.

In this review, the authors highlight the FDA approval of Ritlecitinib, the first oral treatment specifically for moderate to severe alopecia areata in patients aged 12 and older, marking a significant advancement in managing this condition.

This review discusses the increasing prevalence of alopecia in younger populations and outlines the need for better understanding its pathogenesis to develop effective treatments. It also examines current FDA-approved drugs and emerging small molecule compounds with potential anti-alopecia effects.